In this interview from the 2012 American Society of Hematology (ASH) Annual Meeting Dr. Oliver Press explains why there is excitement around antibody-drug conjugates (ADC). ADC allows doctors to selectively focus the drug on the cancer cells reducing the amount of drugs required overall. It is a targeted therapy that should cause a better response in the tumor and minimize toxicity for the patient. Within the last few years, chemists have come up with linkers that keep the drug on antibody until they are delivered to the cancer cell. The first successful ADC for lymphoma was brentuximab vedotin, which is now FDA approved and works well with patients who have relapsed with Hodgkin's lymphoma or T-cell lymphoma. Antibody-drug conjugates are now available in the treatment of B-cell lymphoma. It provides a new targeted approach, a more convenient infusion, and reduced side effects.